MedTrace Logo

Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer

NCT02547987 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-03-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the combination of docetaxel and carboplatin is an effective treatment for patients with triple negative breast cancer.

Conditions

Interventions

DRUG

Docetaxel

Docetaxel 75 mg/m2 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6

DRUG

Carboplatin

Carboplatin AUC 6 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6

Sponsors & Collaborators

  • Mothaffar Rimawi

    lead OTHER

Principal Investigators

  • Mothaffar Rimawi, MD · Baylor College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-01
Primary Completion
2019-06-25
Completion
2025-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02547987 on ClinicalTrials.gov